Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-02-08

Clinical Trial Update: A Study of IBI311 in Subjects With Active Thyroid Eye Disease [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial update for IBI311 in active thyroid eye disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBI311

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Thyroid Eye Disease | Phase 2, Phase 3 | Status: COMPLETED